TLR7 and influenza: In another study, a licensed quadrivalent inactivated influenza vaccine (QIV) administered with RIG-I (SDI-nanogel) and TLR7/8 agonist (Imidazoquinoline) enhanced antibody and T cell responses, correlating with the protection against lethal influenza virus infection (Jangra et al., 2022).